期刊文献+

雌激素受体拮抗剂对泌乳素腺瘤GH_3细胞增殖的影响

Effects of Estrogen Receptor Antagonists on the Growth and Proliferation of Pituitary GH_3 Cell
下载PDF
导出
摘要 目的:探讨雌激素受体拮抗剂对泌乳素腺瘤细胞增殖的影响。方法:在同样去激素培养的条件下添加不同浓度雌激素和雌激素受体拮抗剂,应用MTT法检测其对GH_3细胞增殖的影响。结果:不同浓度的OHTam对GH_3细胞有明显的抑制作用,并且与剂量呈正相关,10^(-11) mol/L即有抑制作用,10^(-6) mol/L抑制作用达到最大。E_2可显著的刺激GH_3细胞增殖,10^(-12)mol/L即有促进增殖作用,10^(-9) mol/L作用达到最大,而后随着浓度的升高增殖作用反而逐渐减弱。结论:雌激素受体拮抗剂能显著抑制泌乳素腺瘤细胞的生长,理论上可以用于泌乳素腺瘤的药物治疗。 Objective:To investigate the effect of estrogen receptor antagonists on the in vitro growth of human prolactinomas.Method:Estradiol and estrogen receptor antagonists were added respectively at different concentrations into the culture medium MTT assays were used to detect the effects on the growth and proliferation of GH3 cells.Result:OHTam could inhibit GH3 cell proliferation as dose-dependent manner,when the concentration was 10^-11 mol/L,the GH3 cell proliferation was inhibit.If the concentration rises to 10^-6 mol/L,it would produce the greatest effect.E2 had significant stimulatory effect on growth of GH3 cells,and the effect worked even at low concentration of 10^-12 mol/L.The greatest effect would produce when the concentration was 10-9 mol/L,if the concentration still increases,the proliferation effect would gradually weaken.Conclusion:Estrogen receptor antagonists can inhibit GH3 cell proliferation.In theory,it can be used for the drug treatment of prolactinomas.
作者 朱正凯 林少华 李亮明 ZHU Zhengkai;LIN Shaohua;LI Liangming(Zhongshan People’s Hospital,Zhongshan 528400,China)
出处 《中国医学创新》 CAS 2019年第10期27-31,共5页 Medical Innovation of China
基金 广东省医学科学技术研究基金项目(A2016535)
关键词 泌乳素腺瘤 雌激素 雌激素受体拮抗剂 GH3细胞 Prolactinomas Estradiol Estrogen receptor antagonists GH3 cells
  • 相关文献

参考文献3

二级参考文献30

  • 1Schlechte JA. Clinical practice. Prolactinoma [J]. N Engl Med, 2003, 349(21): 2035-2041.
  • 2Lloyd RV. Estrogen-induced hyperplasia and neoplasia in the mt anterior pituitary gland. An immunohistochemical study [J]. Am J Pathol, 2003, 113(2): 198-206.
  • 3Yamakawa K, Arita J. Cross-talk between the estrogen receptor-, protein kinase A-, and mitogen-activated protein kinase-mediated signaling pathways in the regulation of lactotroph proliferation in primary culture [J]. J Steroid Biochem Mol Biol, 2004, 88(2): 123-130.
  • 4Li C, Sun Z, Gui S, et al. Effects of fulvestrant, an estrogen receptor antagonist, on MMQ cells and its mechanism [J]. Neuro Endocrinol Lett, 2009, 30(2): 268-274.
  • 5Lopez JM, Oestreicher E. Reversal of hypogonadotropic hypogonadism with tamoxifen in a patient with hyper- prolactinemia resistant to dopamine agonists [J]. Fertil Steril, 2005, 84(3): 756.
  • 6Dadiboyena S. Recent advances in the synthesis of raloxi- fene: a selective estrogen receptor modulator [J]. Eur J Med Chem, 2012, 51: 17-34.
  • 7Wang H, Gorpudolo N, Behr B. The role of prolactin- and endometriosis-associated infertility [J]. Obstet Gynecol Surv, 2009, 64(8): 542-547.
  • 8Cosma M, Bailey J, Miles JM, et al. Pituitary and/or peri- pheral estrogen-receptor alpha regulates follicle- stimulat- ing hormone secretion, whereas central estrogenic path- ways direct growth hormone and prolactin secretion in postmenopausal women [J]. J Clin Endocrinol Metab, 2008, 93(3): 951-958.
  • 9Leung G, Tsao SW, Wong YC. The effect of flutamide and tamoxifen on sex hormone-induced mammary carcino- genesis and pituitary adenoma [J]. Breast Cancer Res Treat, 2002, 72(2): 153-162.
  • 10Laverty HG, Wakefield LM, Occleston NL, et al. TGF- beta3 and cancer: a review [J]. Cytokine Growth Factor Rev, 2009, 20(4): 305-317.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部